Sales tax hike to 18% expected to raise medicine prices

Sales tax is also imposed on diagnostic kits/equipment across various specialties, including cardiology, neurology, oncology, and urology 

Hoechst Pakistan to acquire products and trademarks from Sanofi affiliates

Board approves strategic acquisition to strengthen product portfolio and market position

Lucky Core seals deal for Pfizer’s Karachi plant, pharma products

Asset Purchase Agreements signed, acquisition includes products such as Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin. 

Searle Company to divest entire stake in Searle Pakistan Limited

Board approves disposal of 100% shareholding; negotiations for terms underway

Lucky Core Industries expands portfolio with Pfizer assets acquisition

Deal includes a manufacturing facility, certain pharma products and trademarks associated with said products

Citi Pharma, Hangzhou Newsea partner to boost local API manufacturing

With an expected annual turnover of Rs15,000m, the JV underscores a push towards reducing import dependence and enhancing local manufacturing infrastructure in Pakistan’s pharmaceutical industry

Saudi investors exit Pakistan’s largest pharmacy chain. What happened and why?

From its origins as part of the Servis Group to multiple changes in ownership since its inception in 2005, Servaid has undergone an eventful two decades in existence

The magic pill for the pharma sector

Will the deregulation in drug pricing policy prove to be the long awaited cure for the pharmaceutical industry?

AGP acquires portfolio of products from American pharma firm Viatris

AGP claims newly acquired products will add Rs20b to annual revenues

PPMA vs DRAP: Pharma crisis continues 

Unavailability of medicines could inevitably trigger national health emergency

Pricing dispute causes shortage of critical medicine

Pharma companies stop, limit production of scores of essential and non-essential medicines as govt rejects demand for 38% hike in prices

Pfizer looks beyond COVID sales with $43b deal for cancer drugmaker Seagen

WASHNGTON: Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatments portfolio, as...

The mechanics behind the panadol shortage

Raids, hoarding and over regulating — You probably need a Panadol to figure out what’s going on

Where did all the Burnol go?

The household product is missing from pharmacies in Pakistan. But its brand recall still holds

Pharmaceuticals: how the locals are beating the multinationals

In a heavily regulated market, the local players have learned to live with the price rules the way they are, while the foreign players still seem to have hope that things will change